NEW YORK (GenomeWeb News) – Compugen said today that it will receive grants totaling around $500,000 from the Office of the Chief Scientist of Israel to fund the firm's drug and diagnostic product candidate discovery activities.

Tel Aviv, Israel-based Compugen said that it would use the grant money to discover additional drug targets for antibody therapeutics and preclinical nucleic acid biomarkers for drug-induced toxicity. The firm said these activities would be based on "modifying and enhancing" its 10 existing discovery platforms.